[go: up one dir, main page]

NO954486D0 - Farmasöytiske formuleringsgrunnlag - Google Patents

Farmasöytiske formuleringsgrunnlag

Info

Publication number
NO954486D0
NO954486D0 NO954486A NO954486A NO954486D0 NO 954486 D0 NO954486 D0 NO 954486D0 NO 954486 A NO954486 A NO 954486A NO 954486 A NO954486 A NO 954486A NO 954486 D0 NO954486 D0 NO 954486D0
Authority
NO
Norway
Prior art keywords
pharmaceutical formulation
formulation basis
basis
pharmaceutical
formulation
Prior art date
Application number
NO954486A
Other languages
English (en)
Other versions
NO954486L (no
Inventor
Hans Georg Weder
Ute Isele
Original Assignee
Ciba Geigy Ag
Vesifact Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag, Vesifact Ag filed Critical Ciba Geigy Ag
Publication of NO954486D0 publication Critical patent/NO954486D0/no
Publication of NO954486L publication Critical patent/NO954486L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO954486A 1994-11-09 1995-11-08 Farmasöytiske formuleringsgrunnlag NO954486L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH337594 1994-11-09
CH59595 1995-03-02

Publications (2)

Publication Number Publication Date
NO954486D0 true NO954486D0 (no) 1995-11-08
NO954486L NO954486L (no) 1996-05-10

Family

ID=25685065

Family Applications (2)

Application Number Title Priority Date Filing Date
NO954486A NO954486L (no) 1994-11-09 1995-11-08 Farmasöytiske formuleringsgrunnlag
NO954485A NO954485L (no) 1994-11-09 1995-11-08 Intravenös opplösning for et staurosporinderivat

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO954485A NO954485L (no) 1994-11-09 1995-11-08 Intravenös opplösning for et staurosporinderivat

Country Status (11)

Country Link
US (1) US5658898A (no)
EP (2) EP0711557A1 (no)
JP (2) JPH08208486A (no)
KR (2) KR960016908A (no)
AU (2) AU3661795A (no)
CA (2) CA2162342A1 (no)
FI (2) FI955311L (no)
HU (2) HUT74423A (no)
IL (2) IL115913A0 (no)
NO (2) NO954486L (no)
NZ (2) NZ280420A (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037192A1 (en) * 1995-05-26 1996-11-28 Vesifact Ag Pharmaceutical and cosmetic compositions containing sphingo- and glycolipids
AU7689996A (en) * 1995-12-12 1997-07-03 Vesifact Ag Cortisone spray for topical administration
DE19622224A1 (de) 1996-02-16 1997-08-21 Max Planck Gesellschaft Phosphatidyloligoglycerine
WO1997048398A1 (en) * 1996-06-18 1997-12-24 Kyowa Hakko Kogyo Co., Ltd. Liposome preparations of indolocarbazole derivatives
US6537561B1 (en) * 1997-02-27 2003-03-25 Nippon Shinyaku Co., Ltd. Fat emulsion for oral administration
NZ504188A (en) * 1997-11-14 2001-10-26 Skyepharma Inc Emulsification process for preparing multivesicular liposomes
TW592713B (en) * 1998-05-11 2004-06-21 Ciba Sc Holding Ag Use of nanodispersions in cosmetic end formulations
TWI241915B (en) * 1998-05-11 2005-10-21 Ciba Sc Holding Ag A method of preparing a pharmaceutical end formulation using a nanodispersion
US7381423B2 (en) 1998-05-11 2008-06-03 Ciba Specialty Chemicals Corp. Use of nanodispersions in cosmetic end formulations
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
EP0988857B8 (en) * 1998-08-31 2006-05-03 Nipro Corporation Nutrient infusion preparation
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
GB9924962D0 (en) * 1999-10-21 1999-12-22 Mrc Collaborative Centre Allosteric sites on muscarinic receptors
HU230798B1 (hu) 2001-10-30 2018-06-28 Novartis Ag Staurosporin-származékok mint az FLT3 receptor tirozin-kináz aktivitás inhibitorai
KR100422763B1 (ko) * 2002-01-17 2004-03-12 주식회사 태평양 경피흡수 촉진 능력이 우수한 식물성 나노입자의 제조 및이를 함유하는 화장료 및 의약용 외용제 조성물
KR100490365B1 (ko) * 2002-04-25 2005-05-17 한불화장품주식회사 화장료용 나노 베지클을 함유하는 화장료 조성물
EP2319493A3 (en) * 2002-07-23 2011-07-27 Novartis AG Ophthalmic ointment composition comprising a drug, an ointment base and a solubilizing/dispersing agent
BR0318166A (pt) * 2003-03-03 2006-04-04 Florian Lang uso de uma substáncia para detectar sgk1, kit para essa detecção, bem como composição farmacêutica que inibe ou ativa a sua expressão e/ou função
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
EP1653973A1 (en) 2003-08-08 2006-05-10 Novartis AG Combinations comprising staurosporines
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
JP5135852B2 (ja) * 2007-03-30 2013-02-06 日油株式会社 可溶化用組成物
KR100849537B1 (ko) * 2007-07-04 2008-07-31 유효경 코엔자임 큐텐의 나노에멀젼 조성물
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
JP2012051823A (ja) * 2010-08-31 2012-03-15 Fujifilm Corp 難容性薬物含有水中油型乳化組成物及びその製造方法
KR101494594B1 (ko) 2011-08-30 2015-02-23 주식회사 종근당 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
WO2013086526A1 (en) * 2011-12-09 2013-06-13 The Regents Of The University Of California Liposomal drug encapsulation
KR101586791B1 (ko) 2012-12-28 2016-01-19 주식회사 종근당 ＧｎＲＨ 유도체의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12285419B2 (en) 2021-10-14 2025-04-29 Pacira Pharmaceuticals, Inc. Bupivacaine multivesicular liposome formulations and uses thereof
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12246092B1 (en) 2024-05-20 2025-03-11 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12280149B1 (en) 2024-05-20 2025-04-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6348214A (ja) * 1986-08-18 1988-02-29 Morishita Seiyaku Kk １−〔２−（２，４−ジクロロフエニル）−３−メチル−１−ペンテニル〕−１ｈ−イミダゾ−ルを含有する水中油型脂肪乳剤
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
CH677886A5 (no) * 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
WO1993015736A1 (en) * 1992-02-18 1993-08-19 Pharmos Corp. Dry compositions for preparing submicron emulsions
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions

Also Published As

Publication number Publication date
FI955311A7 (fi) 1996-05-10
FI955312L (fi) 1996-05-10
CA2162341A1 (en) 1996-05-10
NO954485D0 (no) 1995-11-08
IL115913A0 (en) 1996-01-31
FI955312A7 (fi) 1996-05-10
AU3661695A (en) 1996-05-23
JPH08208522A (ja) 1996-08-13
HU9503198D0 (en) 1996-01-29
AU3661795A (en) 1996-05-23
NZ280420A (en) 1997-03-24
FI955312A0 (fi) 1995-11-06
JPH08208486A (ja) 1996-08-13
CA2162342A1 (en) 1996-05-10
EP0711557A1 (de) 1996-05-15
NO954486L (no) 1996-05-10
HUT74423A (en) 1996-12-30
NZ280419A (en) 1997-04-24
EP0711556A1 (de) 1996-05-15
NO954485L (no) 1996-05-10
FI955311L (fi) 1996-05-10
FI955311A0 (fi) 1995-11-06
KR960016890A (ko) 1996-06-17
US5658898A (en) 1997-08-19
IL115912A0 (en) 1996-01-31
KR960016908A (ko) 1996-06-17
HU9503199D0 (en) 1996-01-29
HUT78026A (hu) 1999-05-28

Similar Documents

Publication Publication Date Title
NO954486D0 (no) Farmasöytiske formuleringsgrunnlag
DE69525148D1 (de) Pharmazeutische formulierung
ID24654A (id) Formulasi farmasi omeprazola
FI20071025L (fi) Farmaseuttisia koostumuksia
BR9500784A (pt) Composto e formulação farmacêutica
BR9504060A (pt) Composto e formulação farmacêutica
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
FI970995L (fi) Farmaseuttisia yhdisteitä
FI971279L (fi) Lääkkeitä
BR9610396A (pt) Formulação farmacêutica
NO20004345D0 (no) Farmasøytisk sammensetning
FI954243A7 (fi) Farmaseuttiset yhdisteet
BR9507768A (pt) Composição farmacêutica
ID16781A (id) Formulasi-formulasi farmasi
TR199501082A2 (tr) Farmasötik formülasyonlar.
LV11727A (lv) Farmaceitiska kompozicija
ITMI941169A0 (it) Formulazioni farmaceutiche
ITMI942166A0 (it) Composizioni farmaceutiche miorilassanti
FI973280A0 (fi) Farmaseuttinen koostumus
FI973230A7 (fi) Uusi farmaseuttinen formulaatio
FI951155L (fi) Farmaseuttinen valmiste
BR9605777A (pt) Composição farmacêutica
FI954050L (fi) Lääkekoostumuksia
FI962738L (fi) Farmaseuttiset koostumukset